IL-12/IL-23单抗-话题@MedSci

[GetTopicListResponse(id=2034066, encodeId=75f62034066a9, content=<a href='/topic/show?id=7486962828' target=_blank style='color:#2F92EE;'>#IL-12/IL-23单抗#</a>, objectTitle=AAD 2020：3期临床证实IL-17A/IL-17F单抗Bimekizumab治疗牛皮癣，优于IL-12/IL-23单抗ustekinumab, objectType=article, longId=195839, objectId=0f4c19583900, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0f4c19583900, replyNumber=0, likeNumber=32, createdTime=2020-07-24, rootId=0, userName=appleandpeer, userId=e05e201, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0f4c19583900, moduleTitle=AAD 2020：3期临床证实IL-17A/IL-17F单抗Bimekizumab治疗牛皮癣，优于IL-12/IL-23单抗ustekinumab, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0f4c19583900)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2034065, encodeId=c4aa20340654d, content=<a href='/topic/show?id=7486962828' target=_blank style='color:#2F92EE;'>#IL-12/IL-23单抗#</a>, objectTitle=英国NICE推荐将IL-12/IL-23单抗ustekinumab，用于治疗活动性中度至重度溃疡性结肠炎, objectType=article, longId=193135, objectId=1689193135a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1689193135a7, replyNumber=0, likeNumber=36, createdTime=2020-09-22, rootId=0, userName=appleandpeer, userId=e05e201, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1689193135a7, moduleTitle=英国NICE推荐将IL-12/IL-23单抗ustekinumab，用于治疗活动性中度至重度溃疡性结肠炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1689193135a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2034067, encodeId=68bd203406e0a, content=<a href='/topic/show?id=7486962828' target=_blank style='color:#2F92EE;'>#IL-12/IL-23单抗#</a>, objectTitle=由于缺乏疗效，强生放弃IL-12/IL-23单抗Stelara治疗系统性红斑狼疮的三期研究, objectType=article, longId=196588, objectId=da7919658856, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=da7919658856, replyNumber=0, likeNumber=34, createdTime=2020-11-25, rootId=0, userName=appleandpeer, userId=e05e201, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=da7919658856, moduleTitle=由于缺乏疗效，强生放弃IL-12/IL-23单抗Stelara治疗系统性红斑狼疮的三期研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=da7919658856)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2034068, encodeId=ae9b20340680d, content=<a href='/topic/show?id=7486962828' target=_blank style='color:#2F92EE;'>#IL-12/IL-23单抗#</a>, objectTitle=IL-12/IL-23单抗Stelara（ustekinumab），获得FDA批准治疗牛皮癣儿童患者, objectType=article, longId=198548, objectId=231019854869, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=231019854869, replyNumber=0, likeNumber=32, createdTime=2020-09-26, rootId=0, userName=appleandpeer, userId=e05e201, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=231019854869, moduleTitle=IL-12/IL-23单抗Stelara（ustekinumab），获得FDA批准治疗牛皮癣儿童患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=231019854869)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2034063, encodeId=434c203406343, content=<a href='/topic/show?id=7486962828' target=_blank style='color:#2F92EE;'>#IL-12/IL-23单抗#</a>, objectTitle=强生宣布其IL-12/IL-23单抗STELARA（ustekinumab）喜获FDA批准治疗中度至重度活动性溃疡性结肠炎, objectType=article, longId=181708, objectId=3487181e0866, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3487181e0866, replyNumber=0, likeNumber=40, createdTime=2020-06-11, rootId=0, userName=appleandpeer, userId=e05e201, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3487181e0866, moduleTitle=强生宣布其IL-12/IL-23单抗STELARA（ustekinumab）喜获FDA批准治疗中度至重度活动性溃疡性结肠炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3487181e0866)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2034064, encodeId=7aa320340642e, content=<a href='/topic/show?id=7486962828' target=_blank style='color:#2F92EE;'>#IL-12/IL-23单抗#</a>, objectTitle=Janssen宣布其IL-12/IL-23单抗Stelara治疗克罗恩病的III期中期分析阳性结果, objectType=article, longId=188168, objectId=b557188168d1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b557188168d1, replyNumber=0, likeNumber=30, createdTime=2020-11-07, rootId=0, userName=appleandpeer, userId=e05e201, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b557188168d1, moduleTitle=Janssen宣布其IL-12/IL-23单抗Stelara治疗克罗恩病的III期中期分析阳性结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b557188168d1)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

IL-12/IL-23单抗

2020-05-29

appleandpeer (审核中...)

前往app查看评论内容

#IL-12/IL-23单抗#

AAD 2020：3期临床证实IL-17A/IL-17F单抗Bimekizumab治疗牛皮癣，优于IL-12/IL-23单抗ustekinumab

2020-07-24

appleandpeer (审核中...)

前往app查看评论内容

#IL-12/IL-23单抗#

英国NICE推荐将IL-12/IL-23单抗ustekinumab，用于治疗活动性中度至重度溃疡性结肠炎

2020-09-22

appleandpeer (审核中...)

前往app查看评论内容

#IL-12/IL-23单抗#

由于缺乏疗效，强生放弃IL-12/IL-23单抗Stelara治疗系统性红斑狼疮的三期研究

2020-11-25

appleandpeer (审核中...)

前往app查看评论内容

#IL-12/IL-23单抗#

IL-12/IL-23单抗Stelara（ustekinumab），获得FDA批准治疗牛皮癣儿童患者

2020-09-26

appleandpeer (审核中...)

前往app查看评论内容

#IL-12/IL-23单抗#

强生宣布其IL-12/IL-23单抗STELARA（ustekinumab）喜获FDA批准治疗中度至重度活动性溃疡性结肠炎

2020-06-11

appleandpeer (审核中...)

前往app查看评论内容

#IL-12/IL-23单抗#

Janssen宣布其IL-12/IL-23单抗Stelara治疗克罗恩病的III期中期分析阳性结果

2020-11-07

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

#IL-12/IL-23单抗#

科室

工具

服务